Guidelines on Diagnosis and Treatment of Malignant Lymphomas

More documents

Recommendations

Info

Treatment Approximately 25% of patients with CLL (ie stable CLL , Binet stage A) do not require treatment and are managed with a watch and wait policy. Indications for treatment are progressive stage A disease or stage B or C CLL. Monotherapy in CLL Traditionally CLL was treated with Chlorambucil with symptomatic intent to control progressive disease or B symptoms. Fludarabine monotherapy results in an increased complete remission rate and longer treatment free intervals. Bendamustine has been recently licensed for the treatment of CLL resulting in response rates of 59% and a median progression free survival (PFS) of 18 months. Combination treatments Combined Fludarabine and Cyclophosphamide (FC) increases oS at 5 years from 44% for Chlorambucil and 48% for Fludarabine to 57% for combined FC. Refractory/ poor risk CLL Patients who are refractory to Fludarabine, have p53 dysfunction or deletion of 17p have a median survival of
Lymphoplasmacytic Lymphoma Definition and Incidence Lymphoplasmacytic lymphoma (LPL) is composed of an admixture of small B lymphocytes, lymphoplasmacytoid cells and plasma cells involving the bone marrow, lymph nodes and spleen and usually associated with a serum paraprotein of IgM subtype. LPL is rare and comprises
Page 1 and 2: Guidelines on Diag
Page 3 and 4: Guidelines on Diag
Page 5 and 6: Standards In Diagnosis of Lymphoma
Page 7 and 8: Standards in Staging of Lymphoma An
Page 9 and 10: Pathologic Diagnosis of Lymphoma Ge
Page 11 and 12: Hodgkin lymphoma and its differenti
Page 13 and 14: Potential diagnostic pitfalls for l
Page 15 and 16: Summary of the usual Immunostaining
Page 17 and 18: Mature B-Cell Neoplasms Mature B-Ce
Page 19: Immunophenotype The tumour cells ex
Page 23 and 24: Splenic Marginal Zone Lymphoma Defi
Page 25 and 26: Extra-nodal Marginal Zone B-Cell Ly
Page 27 and 28: Persistent / progressive disease or
Page 29 and 30: Follicular Lymphoma Definition and
Page 31 and 32: Potential Pitfalls a. Failure to di
Page 33 and 34: Mantle Cell Lymphoma Definition and
Page 35 and 36: Diffuse Large B-Cell Lymphoma Defin
Page 37 and 38: Stage 1 (bulky) and stages II - IV
Page 39 and 40: Treatment Standard chemotherapy for
Page 41 and 42: Burkitt Lymphoma/Leukaemia Definiti
Page 43 and 44: CODOX-M, (3 cycles) for low risk di
Page 45 and 46: Potential pitfalls Failure to diffe
Page 47 and 48: Precursor T Cell Neoplasms PRECURSO
Page 49 and 50: Mature T-Cell and NK-Cell Neoplasms
Page 51 and 52: Potential Pitfalls Treatment planni
Page 53 and 54: Recommended Investigations Evaluati
Page 55 and 56: Mycosis Fungoides and Sézary Syndr
Page 57 and 58: ■ ■ Lymph node biopsy if there
Page 59 and 60: Primary Cutaneous CD30-Positive T-C
Page 61 and 62: Angioimmunoblastic T-Cell Lymphoma
Page 63 and 64: Prognostic factors The IPI is of li
Page 65 and 66: Hodgkin Lymphoma (HL) Definition an
Page 67 and 68: Prognostic Factors / Index: i. Earl
Page 69 and 70: Immunodeficiency Associated Lymphop
Page 71 and 72:
of cases and EBV in about 50%, but
Page 73 and 74:
Common Issues in Lymphoma Managemen
Page 75 and 76:
Tumour Lysis Syndrome Tumour Lysis
Page 77 and 78:
Haematopoietic Recombinant Growth F
Page 79 and 80:
Follow-Up Follow-up for patients wi
Page 81 and 82:
Follow-up for patients with concern
Page 83 and 84:
77 Appendix
Page 85:
Lower border: The lower of (i) 5 cm
Page 88 and 89:
Glossary of Treatment Regimens Chlo
Page 90:
2nd Edition. May 2010. Supported by
show all

Guidelines on Diagnosis and Treatment of Malignant Lymphomas

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?